Evidence map›Paper›PMID 32015827›Full record

ArticleClinical and translational allergy2020

Modified protocol of omalizumab treatment to prevent carboplatin-induced drug hypersensitivity reactions: a case study.

Hanneke N G Oude Elberink, Mathilde Jalving, Hilda Dijkstra, Annick A J M van de Ven

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Using Biologics in the Prevention of Anaphylaxis.Current allergy and asthma reports · 2025
    Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hanneke N G Oude Elberink1Department of Allergology and Internal Medicine, Internal address code AA21, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Mathilde Jalving1Department of Allergology and Internal Medicine, Internal address code AA21, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Hilda Dijkstra1Department of Allergology and Internal Medicine, Internal address code AA21, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
Annick A J M van de Ven1Department of Allergology and Internal Medicine, Internal address code AA21, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.ORCID 0000-0001-7032-9571

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carboplatin administration can usually be safely continued via a so-called desensitisation protocol when hypersensitivity reactions arise. Severe break-through reactions that occur early during desensitisation are likely to be IgE-mediated; in that case, addition of omalizumab premedication should be strongly considered.

Indexed as

CarboplatinDesensitisationDrug hypersensitivityOmalizumab

Identifiers

PMID32015827
PMCPMC6990484

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.